*Congreso gratuíto para los estudiantes de la Universidad de Valencia


The II Spanish Meeting on Oligonucleotide Therapeutics (SMOT 2) is an Interdisciplinary Congress focused on the promotion of oligonucleotide-based therapies that will be held in Valencia on 28-29 November 2019.

Last year, the first congress was a success of content and participation and we are ready to make the second edition even better. For this, we are preparing a scientific program of excellence, with top-level national and international speakers and a large number of industry representatives.

We will deal with current and burning issues of the present, but, above all, we will discuss new concepts and paradigms, about new technologies and their impact in the clinical field.

Abstracts for posters should be sent before 30th October (max. 250 characters) to Mbeatriz.llamusi@uv.es, specifying only poster or poster flash presentation.

The poster size is an A0 poster in ‘Portrait’ (vertical) format (A0 measures: 841mm wide x 1189mm high). Please note that there is not enough space for posters bigger than the stated size or posters in landscape. No audio-visual equipment is allowed at the posters.

Thursday 28th November

Session I: Chemical diversity and synthetic issues (9:00-11:00 am)

  1. Mano Manoharan (Alnylam): «Realizing the promise of RNAi Therapeutics through Biomimetic Chemistry of siRNAs“
  2. Juergen Mueller (LGC Axolabs): “LGC’s Contribution to Accelerate Nucleic Acid Medicines “
  3. Marc Caminals (Nitto Avecia): “Steps of an Oligo project from CMO perspective”
  4. Tamara Martínez (Sylentis): Drugs 2.0. “siRNA-based therapies generated by artificial intelligence (AI)”

Coffee break (11-11:30)

Poster Flash presentations (11:30-14:00)

Lunch break (14:00-15:30) Posters visualization (group A)

Session II. Delivery of therapeutic oligonucleotides (15:30-17:30)

  1. Virginia Arechavalagomeza (Biocruces Institude, Bilbao): “Delivery of antisense therapeutics: the last hurdle for successful therapies”
  2. Ramón Eritja (IQAC, Barcelona): “DNA nanostructures for delivery of therapeutic oligonucleotides”
  3. Carles J. Ciudad (University of Barcelona): “PolyPurine Reverse Hoogsteen (PPRH) hairpins oligonucleotides: design, usage and delivery”

Posters visualization (group B) (17:30-19:00)

Friday 29th November

Session III. Discovery and preclinical studies (9:00-11:00 am)

  1. Beatriz Llamusí (University of Valencia): “ARTHEx-DM, antisense RNA therapeutics in Myotonic Dystrophy”
  2. Belinda Cowling (Dynacure): Targeting dynamin 2 in Centronuclear Myopathies with antisense oligonucleotides: pathogenesis and therapies
  3. Peter E. Nielsen (University of Copenhagen): “Precision PNA-antisense antibiotics against multidrug resistant Gram-negative bacteria“
  4. Lucia Echevarria (SQY therapeutics): “Preclinical safety evaluation of tcDNAs”
Coffee break (11-11:30)

Session IV Clinical studies (11:30-14:00)

  1. Marga Galan and Arancha Maciá (Experior): “Research and clinical trials, the Role of the CRO”
  2. Alex McCampbell (Biogen): “Identification and development of ASOs for treatment of familiar ALS”
  3. Shalini Andersson (AstraZeneca): “Exploiting targeted devilery of antisense oligonucleotides to treat metabolic diseases”
Lunch break (14:00-15:30) Posters visualization (group C)

Session V. Regulatory and IP issues. (15:30-16:30)

  1. Lidia Cánovas (Asphalion): “Regulatory considerations for therapeutic oligonucleotides”
  2. Gustavo Fuster (Hoffmann Eitle): “Patents and trade marks, at national, Community and international level”
  3. Joaquín Sáez (Ecrin España): «Translational research from a multistakeholder perspective: from the idea to its practical implementation“
  4. Gonzalo Calvo Rojas (Medicament): «Translational research from a multistakeholder perspective: the regulatory viewpoint“

Round table. (16:30-18:30). Effective translation of research

  • Esther Rimbau (Upf Ventures)
  • Jose Mesa (La Caixa Foundation)
  • Gema Tur (Agencia Valenciana de la innovación)
  • Lluis Pareras (IN VIVO ventures)
  • Ana Isabel Jiménex (Sylentis and ASEBIO)
  • Lucas Martinez Clar (DCN)

Auditorium Marie Curie (PCUV)

C/ Catedrático Agustín Escardino, nº 9, 46980 Paterna, Valence


logo, parc científic